Research Article
Association of Plasma Myeloperoxidase Level with Risk of Coronary Artery Disease in Patients with Type 2 Diabetes
Table 1
Clinical characteristics of subjects in non-CAD and CAD groups.
| | | Non-CAD (5) | CAD
() | value |
| | Age (y) | | | 0.425 | | Sex (male %) | 69.6% | 74.0% | 0.175 | | Disease duration (year) | | | 0.028 | | BMI (kg/m2) | | | 0.656 | | WHR | | | 0.044 | | SBP (mmHg) | | | 0.022 | | DBP (mmHg) | | | 0.195 | | Current smoker, (%) | 27 (20%) | 86 (42.2%) | 0.018 | | TC (mmol/L) | | | 0.014 | | TG (mmol/L) | | | 0.036 | | HDL-C (mmol/L) | | | 0.012 | | LDL-C (mmol/L) | | | 0.042 | | FBG (mmol/L) | | | 0.015 | | HbA1c (%) | | | 0.006 | | MPO (ng/mL) | | | 0.002 | | Insulin therapy (%) | 21 (22.1%) | 45 (21%) | 0.558 | |
Sulfonylurea (%) | 43 (45.3%) | 103 (48.1%) | 0.476 | | Metformin (%) | 68 (71.6%) | 67 (78%) | 0.522 | | Thiazolidinedione (%) | 20 (21.1%) | 38 (17.8%) | 0.485 | | ARB or ACE inhibitors (%) | 45 (47.4%) | 128 (62.1%) | 0.079 | | Calcium channel blocker (%) | 24 (25.3%) | 62 (29%) | 0.245 | | Beta blocker (%) | 14 (14.7%) | 36 (16.8%) | 0.317 | | Statins (%) | 58 (61.1%) | 146 (68.2%) | 0.326 |
|
|
